Covid vaccine makers shift focus to booster shots By Reuters

© Reuters. Health professional prepares Moderna vaccine dose against Covid-19 for application in Zurich 11/17/2021 REUTERS/Arnd Wiegmann

By Michael Erman and Manas Mishra

(Reuters) – Covid-19 vaccine makers are shifting focus and planning a smaller, more competitive market for booster vaccines after delivering as many doses as quickly as possible over the past 18 months.

Executives from the largest Covid vaccine manufacturers, including pfizer (NYSE:) and Modern (NASDAQ:), said they believed most people who wanted to be vaccinated against the disease had already done so — more than 5 billion people worldwide.

In the coming year, most Covid vaccines will be booster shots, or first immunizations for children, which are still receiving regulatory approvals around the world, they said.

Pfizer, which makes its vaccine with Germany’s BioNTech (NASDAQ:) (SA:), and Moderna (NASDAQ:) (SA:) still see an important role for themselves in the market, even as overall demand declines.

The American vaccine maker Novavax (NASDAQ:) and Germany’s CureVac, which is working with GlaxoSmithKline, are developing vaccines they hope to hit the booster market.

The holdings of AstraZeneca (LON:) and Johnson & Johnson (NYSE:), whose injections have been less popular or effective, are expected to decline in this market.

“It becomes a very competitive game with companies fighting for price and market share, even for vaccines considered to be better, like Pfizer and Moderna,” said Hartaj Singh, an analyst at Oppenheimer & Co.

Source link

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button